Click here to go to the previous page
TTP Pathophysiology (+ADAM TS 13) and Treatment: A Nurses Perspective
Program Code:
084577
Date:
Wednesday, June 4, 2008
Time:
2:00 PM to 3:30 PM
EST
DIRECTOR
:
Patricia Jost Golden, RN, HP(ASCP)
MODERATOR
:
Jeffrey Winters, MD, Director Therapeutic Apheresis Unit/Transfusion Medicine Fellowship Program, Mayo Clinic-Rochester
SPEAKER
:
Patricia Jost Golden, RN, HP(ASCP)
Description
This audioconference focuses on thrombotic thrombocytopenic purpura (TTP) pathophysiology and treatment from a nurse's perspective. Research has characterized the von Willebrand factor protease associated with the pathogenesis of TTP as ADAMTS-13, which may prevent inappropriate microvascular platelet aggregation. Deficiency of ADAMTS-13 has been associated with TTP in some patients. An apheresis nurse will discuss the role of ADAMTS 13 in the pathophysiology of TTP and the treatment of this disease with therapeutic plasma exchange (TPE), including a review of procedural parameters and conditions.
LEARNER OUTCOMES:
-
Define etiology, clinical manifestations and diagnosis of thrombotic thrombocytopenic purpura (TTP).
-
Describe the treatment options for TTP.
-
Explain the role of ADAM TS 13 influence in the pathophysiology of TTP.
| CE Category | CE Value |
|---|
|
California Clinical Laboratory Personnel |
1.5 |
|
California Nurse |
1.8 |
|
Florida Laboratory Personnel |
1.8 |
|
General Attendee |
1.5 |
|
Physician |
1.5 |
Please note: Continuing education (CE) credit is available for online offerings only. Individuals that purchase CD-ROMs will not receive CE credit for the programs they view.